Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Kim N., Bernhard J. Eigl et al.|Cancer Discovery|2018Cited by 520
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionMatti Annala, Alexander W. Wyatt, Sinja Taavitsainen et al.|Clinical Cancer Research|2021Cited by 94
Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapyAlexander W. Wyatt, K.N. Chi, Matti Annala et al.|Annals of Oncology|2016Cited by 6
Tables S1 - S10 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionMatti Annala, Alexander W. Wyatt, Sinja Taavitsainen et al.|Unknown|2023Cited by 0